Geron Corporation (NASDAQ:GERN) Receives $4.61 Average Price Target from Brokerages

Shares of Geron Corporation (NASDAQ:GERN - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the ten analysts that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $4.61.

A number of brokerages have recently weighed in on GERN. The Goldman Sachs Group began coverage on Geron in a report on Thursday, July 10th. They issued a "sell" rating and a $1.00 price target for the company. Scotiabank downgraded Geron from a "sector outperform" rating to a "sector perform" rating and lowered their price target for the company from $4.00 to $1.50 in a report on Thursday, May 8th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Integrated Wealth Concepts LLC acquired a new position in Geron during the 4th quarter valued at approximately $36,000. GF Fund Management CO. LTD. acquired a new position in Geron during the 4th quarter valued at approximately $45,000. 111 Capital acquired a new position in Geron during the 4th quarter valued at approximately $52,000. Fifth Lane Capital LP acquired a new position in Geron during the 4th quarter valued at approximately $53,000. Finally, Harvest Investment Services LLC acquired a new position in Geron during the 4th quarter worth $61,000. Institutional investors and hedge funds own 73.71% of the company's stock.

Geron Stock Down 1.9%

GERN stock traded down $0.03 during midday trading on Tuesday, hitting $1.27. 2,119,023 shares of the company's stock were exchanged, compared to its average volume of 11,169,721. The company has a current ratio of 7.87, a quick ratio of 6.97 and a debt-to-equity ratio of 0.44. Geron has a 12-month low of $1.17 and a 12-month high of $4.89. The firm has a 50 day moving average price of $1.43 and a 200-day moving average price of $1.89. The stock has a market capitalization of $805.70 million, a price-to-earnings ratio of -6.02 and a beta of 0.64.

Geron (NASDAQ:GERN - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.01. Geron had a negative return on equity of 47.86% and a negative net margin of 119.54%. The company had revenue of $39.60 million for the quarter, compared to the consensus estimate of $49.88 million. During the same period in the previous year, the business earned ($0.07) EPS. Geron's revenue for the quarter was up 12927.3% compared to the same quarter last year. On average, analysts anticipate that Geron will post -0.25 EPS for the current year.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.